Subtype
WHO Grade 2 Glioma
CI-CAN-00007115Explore in graph →
Non-malignant84 active trials28 evidence items
- NCIt
- C132505
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007115Explore in graph →
Clinical trials
255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00165360 | Prolonged Daily Temozolomide for Low-Grade Glioma | completed | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00591058 | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | unknown | Phase 1 | 36 | TransMolecularINDUSTRY | 1 | Jul 17, 2009 | clinicaltrials |
| NCT00683761 |
| A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma |
| unknown |
| Phase 1 / Phase 2 |
| 64 |
| TransMolecularINDUSTRY |
| 1 |
| Jul 17, 2009 |
| clinicaltrials |
| NCT00080054 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | completed | Phase 1 | 24 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00717210 | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide(NOA-04) | completed | Phase 3 | 318 | Neuro-Oncology Working Group of the German Cancer SocietyNETWORK | 1 | Jul 17, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Nov 2, 2009source: clinicaltrials